Ambroxol, long used for coughs in Europe, stabilized symptoms and brain-damage markers in Parkinson’s dementia patients over ...

Ambroxol is commonly used as an expectorant in cough syrup, helping thin out mucus so people with respiratory illnesses can ...

A safe and affordable treatment to slow the advancement of Parkinson's dementia has emerged – in the form of a commonly ...

Ambroxol – a common cough medicine in Europe – may prevent the progression of dementia in patients with Parkinson's disease, a new trial suggests.

A common cough syrup, Ambroxol, has shown potential in slowing the progression of Parkinson's dementia in a recent clinical trial.

Researchers at Lawson Research Institute (Lawson), the research arm of St. Joseph's Health Care London, are investigating ...

A 12-month study found that Ambroxol helped stabilised psychiatric symptoms and protected against brain damage in genetically ...

A commonly sold cough syrup in Europe could potentially slow down progression of dementia in patients with Parkinson’s ...

A clinical trial has revealed that Ambroxol, a common cough medicine in Europe, may help slow cognitive decline in people with Parkinson’s disease dementia.

Ambroxol supports a key enzyme called glucocerebrosidase (GCase), which is produced by the GBA1 gene. In people with Parkinson's disease, GCase levels are often low.

A cough medicine used for decades in Europe called ambroxol has shown promise for treating dementia in people with ...

Ambroxol boosts levels of an enzyme called GCase, which is known to help clear away waste products which have gathered in brain cells. In Parkinson’s, a build up of a troublesome protein called ...